Aranesp® is also available in 150, 200, 300, and 500 mcg dose strengths. Aranesp® is available in single-dose vials and prefilled syringes, except the 10, 150, and 500 mcg dose strengths, which are available only as prefilled syringes.
The IV route of administration is recommended for adult patients on hemodialysis.
Aranesp® single-dose strengths can be
precisely titrate doses and individualize anemia
for patients with CKD on dialysis.1,*
With the 10 mcg dose strength, doses can be precisely
titrated within 5 mcg intervals.1,*
*Except 15 mcg dose.
DOWNLOAD Prescribing Information
Take a glance at the following doses to see which
single-dose strengths may be combined to individualize anemia management.
ARANESP® SINGLEJECT® PREFILLED SYRINGES
Following initiation of therapy and after each
adjustment, monitor Hb at least weekly
until the Hb
is stable and sufficient to minimize
the need for
When adjusting therapy, consider Hb rise, rate of decline,
responsiveness, and Hb variability.
Patients with CKD and an insufficient Hb
response to ESA therapy or a rate of Hb rise
of > 1 g/dL over 2 weeks may be at an even
greater risk for cardiovascular reactions
and mortality than other patients.
The dose conversions depicted above do not accurately estimate the once-monthly dose of Aranesp® in patients with CKD not on dialysis.
†For pediatric patients receiving a weekly epoetin alfa dose of < 1,500 units/week. The available data are insufficient to determine an Aranesp® conversion dose.
Remember to convert your patient's previous epoetin alfa per-administration dose to a per-week measurement. Here's an example how1:
Important Safety Information including Boxed WARNINGS